Introduction
clinical use of autologous MSC from patients treated with chemotherapy is feasible and does not entail the risk of immunorejection.
A [11] . Clinical trials with TRAIL or DR agonists are currently performed including patients with CRC [12] . However, in vitro studies demonstrate a resistance of some CRC-cell lines for soluble TRAIL-induced apoptosis [13, 14] . [15] [16] [17] [18] and thus, the application of such cells could achieve a lasting intratumoral presence of TRAIL.
candidate for a potent anti-tumour transgene is Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) which induces apoptosis through binding on death receptors (DR) leading to activation of the extrinsic apoptosis pathway via caspase-8. Generally, tumour cells show a higher sensitivity for TRAIL-induced apoptosis presumably due to a higher expression of death receptors in tumour cells and expression of decoy receptors in non-malignant cells

Aside from such resistance a low half-life of soluble TRAIL could hamper therapeutic applications as a permanent intratumoral presence of TRAIL would be favourable. As demonstrated by in vitro models TRAIL-transgenic progenitor or stem cells can exert a strong anti-tumour activity in adjacent tumour cells
Transfection of MSC with bacterial plasmids results in a low frequency of stable genomic transgene insertion [19] . As in vitro cultured MSC populations may contain a considerable amount of quiescent cells [20] , the use of lentiviral systems which allow an efficient genomic transgene integration even in quiescent cells seems favourable [21, 22] .
Data on the effect of TRAIL-MSC on CRC cells in vitro and in vivo are missing. Starting from the observation of resistance of MSC to soluble TRAIL and the known TRAIL sensitivity of selected CRC-cell lines we generated human MSC expressing a lentiviral TRAIL construct and analysed their characteristics. TRAIL-MSC showed not only activity in TRAIL-sensitive CRC cells but also in two CRC-cell lines resistant to soluble TRAIL. We were able to show activity of TRAIL-MSC in vivo; nonetheless the activity of systemically applied TRAIL-MSC seemed to be hampered by their pulmonary entrapment. Our data suggest that a substantial amount of tumour-integrating TRAIL-MSC is required to exert a relevant anti-tumour activity. In addition our data suggest a tumour-supporting activity of wild-type MSC (WT-MSC). Therefore, our study supports the use of transgenic MSC for tumour therapy but also demonstrates the need for further studies before clinical applications can be ventured.
Material and methods
MSC, cell lines and cell culture
Cultivation as well as analysis of growth kinetics and differentiation of MSC isolated from human bone marrow according to a protocol approved by the institutional Ethics Board were performed as described previously [10] with the following modifications. Growth 
Flow cytometry
Flow cytometry was performed as described previously [10] . 
Western blotting
Western blot analyses were performed as described previously [10] 
Immunohistochemistry
Immunohistochemical staining of paraffin slides was performed as described previously [25] 
Statistical analysis
Statistical analysis was performed with SPSS 14.0 software (SPSS Inc. Chicago, IL, USA). An updated t-test including Levene testing for variances was used. A P-value Ͻ0.05 was considered significant.
Results
Stable expression of TRAIL at the cell surface of MSC upon lentiviral transduction
Human MSC showed no morphological signs of apoptosis induction upon treatment with soluble TRAIL for 24 hrs, particularly no detachment of cells (Fig. 1A) and also no staining with annexin V (data not shown). We concluded that TRAIL could serve as a factor to be expressed in MSC in order to mediate an anti-tumour effect by tumour-integrating TRAIL-transgenic MSC. TRAIL-MSC were generated through lentiviral transduction of MSC (for lentiviral construct see Fig. 1B). Western blot analyses of whole protein lysates revealed TRAIL expression at the size of the membrane bound protein (34 kD) over up to nine passages (Fig. 1C). Immunocytochemical analysis with two different antibodies raised against an extracellular domain of human TRAIL indicated presence of TRAIL at the cell surface (Fig. 1D). Incubation with control mouse IgG1 did not result in detectable staining (data not shown) and no TRAIL expression could be detected in WT-MSC (Fig. 1C, D). At passage 4 after transduction approximately 80% of the cells showed TRAIL expression in immunocytochemical analysis (data not shown). Thus, lentiviral transduction of human MSC with TRAIL yielded an efficient and stable transgene expression with localization of TRAIL at the cell surface. Next we wanted to investigate whether lentiviral TRAIL expression altered the defining properties of MSC.
Unaltered MSC characteristics in TRAIL-MSC
We analysed TRAIL-MSC for their MSC characteristics as defined by consensus criteria [5]. Flow cytometric analyses revealed an identical immunophenotype for TRAIL-MSC and WT-MSC, i.e. CD14
Ϫ , CD19 (Fig. 2D) , indicating that transgenic TRAIL did not mediate apoptosis induction in TRAIL-MSC. These data were in accordance with the observed similar proliferation of TRAIL-MSC and WT-MSC (Fig. 2C) . (Fig. 3A) . When cocultures containing TRAIL-MSC were supplemented with TRAIL-neutralizing antibody, no cell detachment was observed (Fig. 3A) .
data not shown). Following adipogenic and osteogenic differentiation induction, TRAIL-MSC showed multipotent differentiation with intracellular accumulation of lipid droplets and calcium deposition, respectively (Fig. 2B). Conclusively, transgenic TRAIL expression in human MSC did not alter their defining MSC characteristics in comparison to
. Whole protein lysates from WT-MSC and TRAIL-MSC were analysed by Western blot for expression of the transmembraneous form of the TRAIL protein (34 kD). Tubulin (55 kD) served as control for equal protein loading. Arrows indicate the respective molecular weight standards in kD. (D) WT-MSC and TRAIL-MSC were fixed on chamber slides and stained with mouse anti-TRAIL (clone ZZ02 and 2E5) and IRDye680 goat antimouse IgG (red). Nuclei were counter-stained with DAPI (blue). Slides were analysed on a Nikon Eclipse TE2000-E. Images are shown as overlays of antibody and DAPI fluorescence. Fluorescence microscopy, original magnification ϫ600.
WT-MSC. As lentiviral transduction poses the risk of oncogene activation we analysed signs of malignant transformation in TRAIL-MSC.
Lack of malignant transformation of TRAIL-MSC
To assess the potential of malignant transformation of TRAIL-MSC we performed growth kinetics, soft agar assays and karyotype analysis with TRAIL-MSC and untransduced WT-MSC from the same donor starting at the time of transduction. TRAIL-MSC showed no changes in proliferation kinetics compared to WT-MSC (Fig. 2C). Neither soft agar colony formation nor karyotypic changes were observed in TRAIL-MSC (data not shown). The transgenic expression of TRAIL may lead to apoptosis induction in transduced cells. However, we observed no increased annexin V-staining in TRAIL-MSC when compared to WT-MSC
Thus, lentiviral expression of TRAIL did neither result in signs of malignant transformation nor in apoptosis induction in human MSC. These data suggested that TRAIL-MSC may serve as a vehicle for tumour growth inhibition and we aimed to investigate their effect on TRAIL-sensitive CRC cells in vitro.
Apoptosis induction in TRAIL-sensitive CRC cells through TRAIL-MSC in vitro
As the CRC-cell line DLD-1 is reportedly sensitive to soluble TRAIL [26], we performed the initial analysis of the tumour-inhibiting capacity of TRAIL-MSC in this cell line. DsRed-DLD-1 cells were exposed to either TRAIL-MSC or WT-MSC in direct cocultures over 24 hrs in vitro. Occurrence of detached cells suggesting apoptosis was observed in cocultures with TRAIL-MSC but not with WT-MSC. These detached cells originated from DLD-1 cells, as shown by their DsRed expression
Direct cell-cell contact was necessary for induction of detachment, as no relevant detachment of cells occurred upon incubation of DLD-1 cells with conditioned medium from TRAIL-MSC cultures (data not shown).
Proliferation (Fig. 3C) (Fig. 3D) (Fig. 3A) and showed no expression of TRAIL (Fig. 3D) . Induction (Fig. 3A) nor cleavage of PARP and procaspases was observed (Fig. 3D) Fig. 4A-a) . The cell lines SW480 and HCT-8 showed continued cell proliferation upon TRAIL treatment and were therefore determined to be TRAIL-resistant (Fig. 4A- Fig. 4A-a) . Fig 4A-b) . (Fig. 4D, E (Fig. 4B) (Fig. 4E) . (Fig. 5A, 
of apoptosis depended on the presence of TRAIL-MSC as in cocultures of DsRed-DLD-1 cells with WT-MSC neither relevant amounts of detached cells occurred
Apoptosis induction in TRAIL-resistant CRC cells through TRAIL-MSC in vitro
Next, we aimed to assess the anti-tumour activity of TRAIL-MSC in other CRC-cell lines. At first we analysed the response to soluble TRAIL in four CRC-cell lines in vitro. Upon TRAIL treatment, a reduction in the cell number below the pre-treatment values was observed for the cell lines HCT-15 and DLD-1. They were thus determined to be TRAIL-sensitive (
a). Growth inhibition occurred to some degree in TRAILresistant CRC-cells lines as demonstrated by the reduced cell numbers in comparison to the respective untreated controls at 24 hrs (
Subsequently, all four CRC-cells lines were directly cocultured with either WT-MSC or TRAIL-MSC. Western blot analyses revealed apoptosis induction as indicated by cleavage of PARP in TRAIL-sensitive CRC-cell lines as well as in the TRAIL-resistant CRC-cells lines SW480 and HCT-8 (
The response to TRAIL-MSC was further investigated in the TRAIL-resistant HCT-8 cell line. DsRed ϩ detached cells were observed after 24 hrs coculture of DsRed-HCT-8 cells with TRAIL-MSC but not in cocultures with WT-MSC (Fig. 4B). As for DLD-1 cells, detachment of DsRed ϩ cells was inhibited by a TRAILneutralizing antibody (Fig. 4B) and required direct cell-cell contact as no relevant detachment of HCT-8 cells occurred upon incubation with TRAIL-MSC conditioned medium (data not shown). Coculture with TRAIL-MSC abolished the expansion of DsRed-HCT-8 cells although in contrast to DLD-1 cells the number of tumour cells at 72 hrs was not reduced in comparison to the initially plated cell numbers (Fig. 4C). The number of detached cells increased over the whole period in coculture with TRAIL-MSC while coculture with WT-MSC resulted in a rapid growth of DsRed-HCT-8 cells without detachment of cells (Fig. 4C). In cocultures with TRAIL-MSC detached cells stained with annexin V and cleavage of PARP, procaspase-8 and procaspase-3 was observed
), supporting the notion of TRAIL-MSC induced apoptosis in HCT-8 cells. Detached cells were positive for DsRed indicating an exclusive induction of apoptosis in CRC cells
Thus, upon direct cell-cell contact in vitro, TRAIL-MSC are capable to induce apoptosis and to inhibit tumour cell growth not only in TRAIL-sensitive CRC-cell lines but also in two CRC-cell lines with proven resistance to soluble TRAIL. We therefore assumed that TRAIL-MSC may be capable of inhibiting tumour growth in vivo.
Reduction of tumour growth involving apoptosis induction by TRAIL-MSC in vivo
We generated s.c. xenografts of DsRed-DLD-1 cells mixed 4:1 with either TRAIL-MSC, GFP-MSC or WT-MSC, i.e. MSC amounting a proportion of 20% of the entire injected cell number. Tumour size was examined by in vivo fluorescence imaging of DsRed fluorescence intensity. After an identical decrease in fluorescence intensity until day 5 the signal intensities from DLD-1 xenografts mixed with GFP-MSC increased whereas intensities from xenografts with TRAIL-MSC remained low
B). This reflected a significant growth inhibition of DLD-1 xenografts by TRAIL-MSC compared to GFP-MSC (P ϭ 0.006; confidence interval 350.3-1128.5) (Fig. 5B) and to WT-MSC (data not shown). A similar difference in tumour growth between xenografts containing WT-MSC and TRAIL-MSC containing xenografts was observed when size and weight of dissected tumours were compared (data not shown). Next, we generated s.c. xenografts of the TRAIL-resistant DsRed-HCT-8 cell line mixed 4 : 1 with either TRAIL-MSC or WT-MSC. As measured by in-vivo imaging, HCT-8 xenografts containing TRAIL-MSC showed reduced growth compared to HCT-8 xenografts containing WT-MSC (Fig. 5C). Similar results were obtained when weight of dissected tumours were compared (data not shown). Thus, tumour-integrated TRAIL-MSC mediated inhibition of tumour growth not only in xenografts from TRAILsensitive DLD-1 cells but also in xenografts from TRAIL-resistant HCT-8 cells. To prove apoptosis induction as the cause for reduced tumour growth we generated xenografts of DsRed-DLD-1 cells mixed with TRAIL-MSC in a proportion of 33:1, i.e. TRAIL-MSC comprising
3% of total cell number injected. This lower proportion was used since the lack of tumour growth with 20% TRAIL-MSC rendered histological examination impossible. A relevant tumour size was reached not earlier than day 7 and tumours were dissected on day 9.
Histochemistry showed staining for cleaved PARP near stromal elements within the tumour (Fig. 5D) indicative for TRAIL-MSC induced apoptosis in CRC cells. (Fig. 6A) . No signs of toxicity were seen upon systemic transplantation of TRAIL-MSC. In particular no organ dysfunction and no formation of additional tumours were observed upon live observation of animals and macroscopic inspection after killing.
We concluded first, that human MSC retained functional expression of lentiviral TRAIL in vivo and second, that TRAIL-MSC can reduce tumour growth of CRC cells in vivo through induction of apoptosis. Given the published data on integration of MSC into tumours we next wanted to investigate the effect of systemically transplanted TRAIL-MSC on the growth of CRC xenografts.
Fig. 4 Apoptosis induction in TRAIL-resistant CRC cells through TRAIL-MSC in vitro. (A) (a) Growing CRC-cell lines were treated for 24 hrs with growth medium (control 24 hrs; white bars) or soluble TRAIL (sTRAIL 24 hrs; grey bars), cell numbers were estimated by a sulforhodamine-B-assay and compared to untreated controls (control 0 hr; black bars). Data are shown as mean Ϯ standard deviation of two independent experiments. (b) CRC-cell lines were cultivated in direct coculture with WT-MSC (W) and TRAIL-MSC (T) for 24 hrs. Whole cell lysates were harvested and analysed by Western blot for cleavage of PARP. Actin served as loading control. Arrows indicate the respective molecular weight standards in kD. (B) DsRed-HCT-8 cells were cultivated in direct coculture with WT-and TRAIL-MSC for 24 hrs. In the far right panel the medium was supplemented with 10 g/ml TRAIL-neutralizing antibody. Light microscopy, original magnification ϫ100. In the lower panel the respective fluorescence images are pictured. (C) DsRed-HCT-8 cells were cocultivated with WT-and TRAIL-MSC, respectively. At the indicated time-points the number of detached cells (grey bars) as well as the proportion of DsRed ϩ HCT-8 cells (white bars) within the total number of adherent cells (black bars) were determined. For comparison, cell numbers at start of coculture (0 hr) were set as 100%. Data are representative of two independent experiments. (D) Detached cells after 48 hrs from (C) were stained with annexin V-FITC (grey filling) and analysed by flow cytometry. As control served untreated DsRed-HCT-8 cells stained with annexin V-FITC (no filling). Data are shown as histograms of fluorescence. (E) Lysates from direct cocultures after 24 hrs were obtained as whole (w) lysates, i.e. all adherent and detached cells combined as well as detached cell (d) lysates from an additional coculture with TRAIL-MSC and subsequently analysed by Western blot. Tubulin served as loading control. Arrows indicate the respective molecular weight standards in kD. '*' indicates the procaspases and 'ϩ' the cleaved fragments. Data are representative of two independent experiments.
Lack of effects of systemic TRAIL-MSC on growth of s.c. CRC xenografts
DiI-labelled TRAIL-or WT-MSC were injected into the tail vein in mice bearing s.c. GFP-DLD-1 xenografts. Tumour size was examined by in vivo fluorescence imaging. In comparison to controls receiving no MSC a similar tumour growth occurred in mice receiving WT-MSC as well as in mice receiving TRAIL-MSC
Ex vivo fluorescence imaging of whole dissected lungs showed strong signals in accordance with a pulmonary entrapment of the applied MSC (Fig. 6B) . Lungs from animals which received no MSC (Fig. 6B) (Fig. 6C) (Fig. 6D) .
as well as dissected s.c. tumours from all animals showed no signals in whole organ fluorescence imaging (data not shown). In cryosections of lungs from animals which received DiI-labelled TRAIL-MSC we saw large areas of red fluorescent cells confirming a pulmonary accumulation of MSC. Cryosection of s.c. tumours from these animals showed only a few DiI signals
Fig. 5 Reduction of tumour growth involving apoptosis induction by TRAIL-MSC in vivo (A) DsRed-DLD-1 cells were mixed with GFP-MSC or TRAIL-MSC at a proportion of 4:1 (i.e. 20% MSC of total cell number injected) and injected in nude mice subcutaneously into the left or right flank, respectively, at day 0. Tumour size on both sides of each animal was examined by imaging the fluorescence intensity of the DsRed signal. Exposure time was set automatically. A representative range of images from one mouse out of three experiments is pictured. (B) DsRed-fluorescence intensities of xenografts from DsRed-DLD-1 cells mixed with 20% GFP-MSC (green square) or 20% TRAIL-MSC (blue triangle) as described under (
Requirement for a substantial proportion of tumour-integrated TRAIL-MSC to inhibit CRC-tumour growth in vivo
However, when the size of xenografts containing TRAIL-MSC were compared to xenografts containing WT-MSC (Fig. 6D) [28] but is comparable to doses used in other in vitro studies [13] . As further dose escalation does not result in altered response [13, 29] [2] [3] [4] ) in models of systemic application [7, 30] , in mixed s.c. xenografts [6] or by intratumoral injection [17] [31] [32] [33] [34] but also of human tumour cells [35] has been reported. It has to be pointed out, that in most of those studies which demonstrated an anti-tumour effect of systemically applied transgenic MSC pulmonary tumour models were used [30, 36, 37] . Thus, such pulmonary entrapment of MSC may explain the increased anti-tumour effect of systemically applied transgenic MSC in pulmonary tumour models compared to s.c. tumour models. However, tumour integration [7, 38, 39] and even proliferation [8] of systemically applied MSC was seen in s.c. tumours in a few studies. To date, no obvious explanation exists for these differential observations. The observed clinical effects of systemically applied MSC in patients [40] [41] [42] [43] [44] [38, [45] [46] [47] and also specifically for CRC-cell lines [48] .
Taken 
